Editorials

Drugs for Alzheimer's disease and related dementias

BMJ 2005; 330 doi: http://dx.doi.org/10.1136/bmj.330.7496.857 (Published 14 April 2005) Cite this as: BMJ 2005;330:857
  1. Serge Gauthier, professor of psychiatry, neurology and neurosurgery, and medicine ([email protected])
  1. McGill Center for Studies in Aging, 6825 LaSalle Blvd, Verdun (Montréal), Québec, Canada H4H 1R3

    Clear rules about stopping treatment in individual patients are needed

    The article by Ballard et al in this issue (p 874) offers an opportunity to discuss the role of drugs in the treatment of Alzheimer's disease and related dementias.1 This investigator driven randomised clinical trial has tested the hypothesis that the atypical neuroleptic quetiapine and the cholinesterase inhibitor rivastigmine would be better than placebo for treating agitation in institutionalised patients in severe stages of Alzheimer's disease. Using measures of agitation (the Cohen-Mansfield agitation inventory) and cognition (the severe impairment battery) appropriate for this stage of dementia, the authors showed that agitation improved equally in the three arms of the trial but a measurable decline in cognition occurred in patients taking quetiapine. …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe